๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Trials with a site in Beijing

25 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
NCT07553793Pancreatic Cancer, Advanced Stage Cancer
Peking Union Medical College Hospital
Phase 1
18
Beijing
2026-05-01
Recruiting
Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia
NCT07670286Pancreatic Cancer, Cachexia; Cancer; Sarcopenia
Peking Union Medical College Hospital
Observational
500
Beijing
2026-04-24
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
NCT07586813Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
Peking University People's Hospital
Phase 2
220
Beijing
2025-12-22
Recruiting
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
NCT07079228Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3
602
Beijing
2025-09-08
Not yet open
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
NCT07114666Pancreatic Cancer
DrugXH001
Peking Union Medical College Hospital
Not applicable
12
Beijing
2025-08-18
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
NCT07066995Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Essen Biotech
Phase 1/2
60
Beijing
2025-04-29
Recruiting
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
NCT06962267Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
50
Beijing
2025-04-18
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
NCT06134960Gastric Cancer, Pancreatic Cancer, Solid Tumor
Peking University
Phase 1
12
Beijing
2024-11-16
Active, closed
MRD in PAAD Adjuvant Therapy
NCT06867146The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy
Peking Union Medical College Hospital
Not applicable
60
Beijing
2024-10-15
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NCT06353646Pancreatic Cancer
Wu Wenming
Not applicable
28
Beijing
2024-03-12
Recruiting
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NCT05802407Pancreatic Cancer, Resectable Carcinoma
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT05802394Pancreatic Cancer, Locally Advanced
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Recruiting
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
Chinese PLA General Hospital
Phase 1/2
90
Beijing
2021-08-04
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
NCT04025840Pancreatic Cancer, Surgery, Epidural Block, Dexamethasone
Peking University First Hospital
Phase 4
260
Beijing
2019-09-11
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

17 of the 25 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 25 studies
PhaseStudiesRecruitingShare
Not applicable5320%
Phase 15420%
Phase 1/25220%
Phase 25420%
Observational228%
Phase 3228%
Phase 4104%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Peking Union Medical College Hospital74
CARsgen Therapeutics Co., Ltd.21
Akeso11
Allist Pharmaceuticals, Inc.11
ArriVent BioPharma, Inc.11
Astellas Pharma Global Development, Inc.10
AstraZeneca10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Chinese PLA General Hospital11
EMD Serono Research & Development Institute, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.